Guidance Provided for PCPs to Identify Biliary Atresia in Newborns by 2 to 4 Weeks
By Elana Gotkine HealthDay Reporter
TUESDAY, Feb. 18, 2025 -- In a clinical report issued by the American Academy of Pediatrics and published online Feb. 18 in Pediatrics, recommendations are presented to assist primary care providers in identifying biliary atresia in newborns by 2 to 4 weeks of life.
Sanjiv Harpavat, M.D., Ph.D., from Baylor College of Medicine and Texas Children's Hospital in Houston, and colleagues provide a strategy that can be used between 2 and 4 weeks of life at the "by 1 month" well-child visit in the Bright Futures/American Academy of Pediatrics "Recommendations for Preventive Pediatric Health Care."
The strategy includes examination of infant eye color, stool color, and prior laboratory results to assess whether drawing a direct or conjugated bilirubin level is warranted. Step 1 assesses whether the eyes or skin appear jaundiced beyond 2 weeks of life; the strategy proceeds to Step 2 even if the answer is no. Step 2 examines whether stools are pale, gray, or white; the strategy proceeds to Step 3 even if the answer is no. Step 3 evaluates at whether bilirubin levels were previously checked and, if so, whether the initial value was above the laboratory's range. The authors note the initial direct or conjugated bilirubin level will be high in biliary atresia, starting at birth. Skin and stool color should continue to be monitored even if the bilirubin levels were not checked or are not above the laboratory range, which could occur if compared with the wrong reference range.
"By identifying infants earlier, primary care providers have a unique opportunity to improve outcomes and help reduce the tremendous liver transplant burden of biliary atresia," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted February 2025
Read this next
Metabolic Dysfunction-Linked Steatotic Liver Disease Tied to Increased Preterm Birth Risk
TUESDAY, May 20, 2025 -- Metabolic dysfunction-associated steatotic liver disease (MASLD) in pregnant women is a risk factor for preterm birth, according to a study published...
Study IDs Trends in 2015 to 2023 Mortality for Chronic Liver Disease
THURSDAY, May 8, 2025 -- Distinct trends were seen in etiology-based mortality with chronic liver disease (CLD) before, during, and after the COVID-19 pandemic, according to a...
DDW: Certain Proteins Predict Metabolic Dysfunction-Associated Steatotic Liver Disease
FRIDAY, April 25, 2025 -- Five proteins are significant predictors of metabolic dysfunction-associated steatotic liver disease (MASLD), according to a study presented at the 2025...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.